Rita A. Karachun
Known title: Sr. VP Fince-Global ControllerCIK: 0001601572
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Merck Stock Rally Draws Attention to Valuation Concerns. Recent market commentary highlights a renewed confidence in Merck, with analysts debating whether the current rally has priced in too much optimism. While comparisons with peers like AbbVie and Bristol Myers Squibb focus on dividend yields and value, the primary discussion centers on the sustainability of Merck's recent price movement. The stock's high trailing P/E ratio of 112.6 provides context for these valuation concerns, suggesting that investors are closely monitoring if the current momentum can be sustained.
Transaction History
| CHRS | ▲ Buy | Grant | 30,000 | $0 | 6/5/2026 | View on chart |
| MRK | ▲ Buy | Option Exercise | 949 | $112K | 5/4/2023 | View on chart |
| MRK | ▼ Sell | Tax Withholding | 326 | $39K | 5/4/2023 | View on chart |
| MRK | ▲ Buy | Option Exercise | 15,875 | $985K | 5/4/2023 | View on chart |
| MRK | ▼ Sell | Open Market | 15,875 | $1.9M | 5/4/2023 | View on chart |
| MRK | ▲ Buy | Option Exercise | 803 | $95K | 5/3/2023 | View on chart |
| MRK | ▼ Sell | Tax Withholding | 276 | $33K | 5/3/2023 | View on chart |
| MRK | ▲ Buy | Option Exercise | 930 | $107K | 5/1/2023 | View on chart |
| MRK | ▼ Sell | Tax Withholding | 319 | $37K | 5/1/2023 | View on chart |
| MRK | ▲ Buy | Grant | 2,846 | $313K | 1/23/2023 | View on chart |
| MRK | ▲ Buy | Option Exercise | 15,000 | $0 | 10/28/2022 | View on chart |
| MRK | ▼ Sell | Open Market | 31,997 | $3.2M | 10/28/2022 | View on chart |
| MRK | ▲ Buy | Option Exercise | 16,997 | $0 | 10/28/2022 | View on chart |
| MRK | ▼ Sell | Tax Withholding | 326 | $28K | 5/4/2022 | View on chart |
| MRK | ▲ Buy | Option Exercise | 949 | $83K | 5/4/2022 | View on chart |
| MRK | ▲ Buy | Option Exercise | 902 | $79K | 5/3/2022 | View on chart |
| MRK | ▼ Sell | Tax Withholding | 309 | $27K | 5/3/2022 | View on chart |
| MRK | ▲ Buy | Option Exercise | 928 | $82K | 5/1/2022 | View on chart |
| MRK | ▼ Sell | Tax Withholding | 318 | $28K | 5/1/2022 | View on chart |
| MRK | ▲ Buy | Grant | 3,478 | $256K | 2/24/2022 | View on chart |
| MRK | ▼ Sell | Open Market | 25,000 | $2.2M | 11/3/2021 | View on chart |
| MRK | ▲ Buy | Option Exercise | 25,000 | $0 | 11/3/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
CHRS Retains Oppenheimer to Market Legacy Biosimilar Assets
Coherus Oncology announced that it has retained Oppenheimer & Co. to market its legacy biosimilar assets. The move aims to increase visibility and potential partnerships for older products in its pipeline. The stock is currently near a long‑standing support level, which may draw attention as the company pursues these marketing efforts.
CHRS Retains Oppenheimer to Market Legacy Biosimilar Assets. Coherus Oncology announced that it has retained Oppenheimer & Co. to market its legacy biosimilar assets. The move aims to increase visibility and potential partnerships for older products in its pipeline. The stock is currently near a long‑standing support level, which may draw attention as the company pursues these marketing efforts.